CN1900120A - Fusion protein containing haman parathyroxin 1-34 and its expression vector - Google Patents
Fusion protein containing haman parathyroxin 1-34 and its expression vector Download PDFInfo
- Publication number
- CN1900120A CN1900120A CNA2006100709954A CN200610070995A CN1900120A CN 1900120 A CN1900120 A CN 1900120A CN A2006100709954 A CNA2006100709954 A CN A2006100709954A CN 200610070995 A CN200610070995 A CN 200610070995A CN 1900120 A CN1900120 A CN 1900120A
- Authority
- CN
- China
- Prior art keywords
- fusion rotein
- sequence
- trx
- peptide
- parathyroid hormone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 11
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 10
- 239000013604 expression vector Substances 0.000 title claims description 19
- 108090000445 Parathyroid hormone Proteins 0.000 claims abstract description 23
- 230000004927 fusion Effects 0.000 claims description 44
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 29
- 239000000199 parathyroid hormone Substances 0.000 claims description 28
- 108010013369 Enteropeptidase Proteins 0.000 claims description 26
- 102100029727 Enteropeptidase Human genes 0.000 claims description 23
- 102000004190 Enzymes Human genes 0.000 claims description 18
- 108090000790 Enzymes Proteins 0.000 claims description 18
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 15
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 13
- 101001135767 Rattus norvegicus Parathyroid hormone Proteins 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 229960001319 parathyroid hormone Drugs 0.000 claims description 9
- 108020004511 Recombinant DNA Proteins 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 230000017854 proteolysis Effects 0.000 claims description 3
- 108060008226 thioredoxin Proteins 0.000 abstract description 22
- 108091005804 Peptidases Proteins 0.000 abstract description 4
- 102000035195 Peptidases Human genes 0.000 abstract description 4
- 102000002933 Thioredoxin Human genes 0.000 abstract 3
- 229940094937 thioredoxin Drugs 0.000 abstract 3
- 108010075254 C-Peptide Proteins 0.000 abstract 1
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 34
- 108090000623 proteins and genes Proteins 0.000 description 33
- 108010049264 Teriparatide Proteins 0.000 description 28
- 241000894006 Bacteria Species 0.000 description 25
- 239000013612 plasmid Substances 0.000 description 20
- 102100036407 Thioredoxin Human genes 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 17
- 238000000034 method Methods 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 108091008146 restriction endonucleases Proteins 0.000 description 10
- 210000000988 bone and bone Anatomy 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 102100036893 Parathyroid hormone Human genes 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 210000003000 inclusion body Anatomy 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 5
- 208000001132 Osteoporosis Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 229920002684 Sepharose Polymers 0.000 description 5
- 238000001042 affinity chromatography Methods 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 238000013016 damping Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 230000009182 swimming Effects 0.000 description 5
- 238000007400 DNA extraction Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000001888 Peptone Substances 0.000 description 4
- 108010080698 Peptones Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 229910001453 nickel ion Inorganic materials 0.000 description 4
- 235000019319 peptone Nutrition 0.000 description 4
- 230000002797 proteolythic effect Effects 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108010059378 Endopeptidases Proteins 0.000 description 3
- 102000005593 Endopeptidases Human genes 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 101710137500 T7 RNA polymerase Proteins 0.000 description 3
- 108020005038 Terminator Codon Proteins 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 238000005349 anion exchange Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000012460 protein solution Substances 0.000 description 3
- 101150072359 trx gene Proteins 0.000 description 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 description 2
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000003277 amino acid sequence analysis Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- MWKXCSMICWVRGW-UHFFFAOYSA-N calcium;phosphane Chemical compound P.[Ca] MWKXCSMICWVRGW-UHFFFAOYSA-N 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 102000058004 human PTH Human genes 0.000 description 2
- 150000002460 imidazoles Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000013001 point bending Methods 0.000 description 2
- 238000011046 pyrogen test Methods 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 102000009310 vitamin D receptors Human genes 0.000 description 2
- 108050000156 vitamin D receptors Proteins 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- UDPGUMQDCGORJQ-UHFFFAOYSA-N (2-chloroethyl)phosphonic acid Chemical compound OP(O)(=O)CCCl UDPGUMQDCGORJQ-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- CFBILACNYSPRPM-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]acetic acid Chemical compound OCC(N)(CO)CO.OCC(CO)(CO)NCC(O)=O CFBILACNYSPRPM-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000005572 Cathepsin A Human genes 0.000 description 1
- 108010059081 Cathepsin A Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- XJQDHFMUUBRCGA-KKUMJFAQSA-N His-Asn-Phe Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O XJQDHFMUUBRCGA-KKUMJFAQSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 241000239218 Limulus Species 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000005267 amalgamation Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000004690 coupled electron pair approximation Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 101150023479 hsdS gene Proteins 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 101150088264 pol gene Proteins 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000012807 shake-flask culturing Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000013456 study Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention provides a kind of fusion protein, which possesses thioredoxin sequence and parathormone peptide 1-34 located in the downstream of the thioredoxin. Preferably, the fusion protein possesses also connecting peptide containing proteolytic enzyme recognizing site and located between the thioredoxin and the parathormone peptide 1-34. From the fusion protein, human parathormone peptide 1-34 may be prepared.
Description
Technical field
The present invention relates to gene engineering technology field, relate in particular to the fusion rotein and the expression vector thereof that contain human parathyroid hormone 1-34.
Background technology
(Parathyroid Hormone is by Rat parathyroid hormone 1-34 chief cell synthetic PTH) to Rat parathyroid hormone 1-34, is made up of 84 amino acid.People recognize that gradually PTH can be increased in osteoblastic quantity very active in the synthetic new ground substance of bone, and can change the genetic expression in the bone in vivo.PTH also has the active effect that brings high blood pressure down, regulates Vitamin D Receptor (VDR) expression, regulates alkaline phosphatase.Tregear etc. (Tregear GW etc., Endocrinology, 1973,93:1349) with experimental results show that PTH performance calcium phosphorus adjusting molecularity only needs an aminoterminal 1-34 amino-acid residue.But PTH (1-34) does not contain halfcystine, and is unstable in vivo.
The genetically engineered research of PTH starts from the eighties in 20th century.The gene engineering method of preparation PTH (1-34) mainly contains two classes at present, and a class is the form preparation with inclusion body, another kind of form preparation with soluble protein.1997, Japanese scientist Yuji Suzuki etc. were with human parathyroid hormone (hPTH (1-34)) and beta-galactosidase enzymes amalgamation and expression, but fusion rotein exists with the inclusion body form.Chinese patent publication number CN1417231A also discloses the method that a kind of form with inclusion body prepares hPTH (1-34).In the method for this class, the fusion rotein that gives expression to needs to cut through inclusion body extraction, dilution refolding, enzyme, carry out means such as ion-exchange, reversed-phase HPLC chromatography then and carry out purifying, just can obtain hPTH (1-34), thereby the preparation process of these class methods is comparatively complicated.
Chinese patent application publication number CN1424325A discloses the preparation technology of a kind of recombinant human parathyroid hormone precursor peptide and recombinant human parathyroid hormone 1-34 peptide.In order to prepare this parathyroid hormone 1-34 peptide, need make engineering bacterium expression go out this fusion rotein of GST-Gly-Ser-Pro-PTH (1-34) earlier, successively the gained fusion rotein is carried out enzyme again and cut, after separation and purification, obtain required parathyroid hormone 1-34 peptide again with zymoplasm and proline(Pro) endopeptidase.Owing to need to use double digestion, the disclosed preparation technology of this patent application is also comparatively complicated.
People know Trx (Thiroedoxin already, hereinafter abbreviate " Trx " sometimes as) be a kind of yeast, bacterium, animal, intravital protein of plant of being prevalent in, this protein also is for example yeast or colibacillary intrinsic protein of present PTH (1-34) expressive host commonly used, utilizes this albumen and PTH (1-34) fusion to prepare hPTH (1-34) easily but also have no talent so far.
Summary of the invention
One aspect of the present invention provides a kind of new fusion rotein, and it has: (1) Trx sequence and (2) are positioned at the Rat parathyroid hormone 1-34 1-34 peptide in described Trx downstream.Comparatively preferably, this fusion rotein also has (3) connection peptides that contains the proteolysis enzyme recognition site between described Trx sequence and described Rat parathyroid hormone 1-34 1-34 peptide.Described proteolytic ferment can be zymoplasm, Kex2-600, proline(Pro) endopeptidase, enteropeptidase.Enteropeptidase is preferred, because that this proteolytic ferment at the described fusion rotein of C-terminal cracking of recognition site, can obtain after enzymic hydrolysis is finished like this is complete, described Rat parathyroid hormone 1-34 1-34 peptide accurately.For the ease of purifying, also preferably have the optional C end that is arranged in described connection peptides or Trx or (His) of N end at fusion rotein of the present invention
6-Tag.Therefore, can utilize gene recombination technology well known in the art, Trx, His-Tag coding region, enteropeptidase recognition site and Rat parathyroid hormone 1-34 1-34 peptide-coding region are connected in turn, thereby obtain Trx-(His)
6-enteropeptidase recognition site-Rat parathyroid hormone 1-34 1-34 peptide.Also the gene of coding Rat parathyroid hormone 1-34 1-34 peptide directly can be inserted into can be from the commercially available suitable expression vector that contains Trx and His-Tag encoding sequence that obtains [for example, pET32a (+)].In a specific embodiment of the present invention, described (His)
6The encoding sequence of-Tag and proteolytic ferment (being specially enteropeptidase) is located in the described connection peptides, and the sequence of gained fusion rotein holds the C end to be from N: Trx-contains (His)
6Connection peptides-Rat parathyroid hormone 1-34 1-34 peptide with the proteolytic enzyme recognition site.
A kind of recombinant DNA sequence of code book invention fusion rotein and the expression vector that contains this sequence are provided in another aspect of this invention.In a specific embodiment, recombinant DNA sequence of the present invention comprises the following nucleotide sequences of coding enteropeptidase recognition site-Rat parathyroid hormone 1-34 1-34 peptide: GACGACGACGACAAGTCCGTTTCCGAAATCCAGCTGATGCACAACCTGGGTAAACA CCTGAACTCCATGGAACGTGTTGAATGGCTGCGTAAAAAACTGCAGGACGTTCACA ACTTC.
Description of drawings
Fig. 1 cuts the evaluation collection of illustrative plates for recombinant expression plasmid pET-PTH (1-34) enzyme.Among Fig. 1, the content of each swimming lane representative is: M, dna molecular amount standard (λ DNA/HandIII, the molecular weight size is marked in a figure left side); 1, recombinant plasmid pET-PTH (1-34); 2, recombinant plasmid pET-PTH (1-34) cuts through the EcoRI enzyme; 3, pET32a (+) plasmid DNA is cut through the PstI enzyme; 4, recombinant plasmid pET-PTH (1-34) cuts through the PstI enzyme.
Fig. 2 is recombinant plasmid pET-PTH (1-34) forward sequencing result.
Fig. 3 is recombinant plasmid pET-PTH (1-34) backward sequencing result.
Fig. 4 is the SDS-PAGE electrophorogram of the expression screening of recon.Among Fig. 4, M, for protein molecular weight standard (the molecular weight size is marked in a figure left side); What swimming lane 1 showed is to induce preceding sampling result; That swimming lane 2-9 shows respectively is 1-8 recon abduction delivering result.
SDS-PAGE electrophoretic analysis after Fig. 5 engineering bacterium fermentation is expressed.Among Fig. 5, M, be protein molecular weight standard, each band molecular weight size (kDa) is marked in a figure left side; What swimming lane 1 showed is the fermentation thalline of collecting; What swimming lane 2 showed is that IPTG induces preceding thalline.
Fig. 6 rhPTH (1-34) respectively goes on foot the SDS-PAGE electrophoretic analysis of purification of samples.Among Fig. 6,1, the fermentation thalline; 2, centrifugal supernatant behind the broken bacterium; 3, nickel ion chelating affinity chromatography sample; 4, the enteropeptidase enzyme of fusion rotein is cut sample; 5, Q Sepharose High Performance column chromatography sample; 6, reversed phase column chromatography sample; 7, SP Sepharose Fast Flow column chromatography sample; M, be protein molecular weight standard, each band molecular weight size (kDa) is marked in the figure right side.
Fig. 7 is that the RP-HPLC of rhPTH (1-34) analyzes collection of illustrative plates.
Fig. 8 is the mass spectroscopy collection of illustrative plates of rhPTH (1-34).
Fig. 9 shows commercially available pET32a (+) plasmid map.
Figure 10 is the dna sequence dna that contains rhPTH (1-34) encoding sequence of synthetic.Wherein, 5 '-CTG and AAG-3 ' cut the protection base for enzyme,
GGTACCBe the KpnI restriction enzyme site, GACGACGACGACAAG is an enteropeptidase restriction enzyme site encoding sequence, TCCGTTTCCGAAATCCAGCTGATGCACAACCTGGGTAAACACCTGAACTCCATGGA ACGTGTTGAATGGCTGCGTAAAAAACTGCAGGACGTTCACAACTTC is the sequence of coding PTH, TAA is a terminator codon
GTCGACBe Sal I restriction enzyme site.
Embodiment
In order to obtain fusion rotein of the present invention, need first structure can express this Expression of Fusion Protein carrier.This expression vector can be inserted into the downstream that is subjected to the Trx gene under the promotor control by the dna sequence dna of the hPTH (1-34) that will encode and make up and finish.As described in the background section, Trx is a kind of yeast, bacterium, animal, intravital protein of plant of being prevalent in, and this protein also is for example yeast or colibacillary intrinsic protein of present hPTH (1-34) expressive host commonly used.This albumen can be regulated the balance of Protein Folding and accumulation process in cell, Trx can interact with many albumen, strengthens the solvability of fusion rotein, thereby has reduced the formation (Thomas of inclusion body, J.G. etc., Appl Biochem Biotechnol.66 (3): 197-238).Can use complete Trx in the present invention, also can use a part or its mutant of Trx, selected part or mutant have and same or analogous space structure of Trx and function.
Expression vector of the present invention can be the zymic expression vector, also can be colibacillary expression vector.Described hPTH (1-34) can be the new dna sequence dna of complete synthetic, also can be the dna sequence dna of disclosed coding hPTH (1-34).For the downstream that the dna sequence dna of the hPTH (1-34) that will encode inserts the Trx gene, preferred use has contained the cloning vector of described Trx gene or its partial sequence.This carrier also can obtain by purchase.For example, pET32a (+) a kind of carrier that comes to this.PET32a (+) can efficiently express the polypeptide that contains 109 amino acid whose Trx-Tag, and after foreign gene inserted its multiple clone site, the fusion rotein of generation contained His-Tag and the S-Tag sequence that can shear, is convenient to detect and purifying.
In order in subsequent step, hPTH (1-34) to be discharged from fusion rotein, preferably introduce proteins encoded lytic enzyme recognition site nucleotide sequence at 5 ' end of the dna sequence dna of coding hPTH (1-34).Described proteolytic ferment can be zymoplasm, Kex2-600, proline(Pro) endopeptidase, enteropeptidase.Enteropeptidase is preferred, because this endonuclease capable is at the C-terminal hydrolysis fusion rotein of recognition site.Therefore, the more preferably direct and then encoding sequence of hPTH (1-34) in the back of the nucleotide sequence of coding enteropeptidase recognition site, like this enteropeptidase can finally required hPTH (1-34) is complete, discharge exactly.If adopt the dna sequence dna of synthetic coding hPTH (1-34),, when the described dna sequence dna of synthetic, also need introduce suitable restriction enzyme site at the 5 ' end and the 3 ' end of this sequence for the ease of the clone.For the ease of purifying in the future, can on the appropriate location of fusion rotein, insert the sequence of being convenient to purifying, for example preferably insert His-Tag at the N of used Trx end or C end.The gene that not only has Trx among the commercially available carrier pET32a (+), and also have His-Tag in the downstream of this gene.
The present invention also provide a kind of on a large scale, hPTH (1-34) expression method efficiently.For a large amount of preparation hPTH (1-34), the recombinant expression vector that makes up need be transformed suitable host's competent cell, for example yeast cell or Bacillus coli cells, and in suitable substratum, ferment, with the results fusion rotein.The host cell that adopts in a specific embodiment of the present invention is can be from the commercially available E.coli BL21 (DE3) that obtains.In the born of the same parents of this cell and the equal inactivation of intercellular periplasm protein enzyme, when carrying out the solubility expression of foreign protein, be not easy like this by the protease hydrolysis of host bacterium, but thereby stable existence.
In order during fermentation effectively to control, but the expression vector of induction type is adopted in suggestion.The pET serial carrier paracolon expression vector that comes to this.This carrier is the E.coli expression vector that utilizes T7 phage rna polymerase/promoter systems to make up, and has promptly integrated the t7 rna polymerase gene on the karyomit(e) of E.coliBL21 (DE3) or JM109 (DE3), and regulated and control by the lac operon.So, when inducing, cause the synthetic of t7 rna polymerase, thereby induced the expression of goal gene on the pET carrier with IPTG.T7 phage rna/promotor has very strong startup activity, and in carrier multiple clone site sequence upstream strong ribosome binding sequence (rbs) is arranged, so the pET carrier can be expressed foreign protein efficiently.
Described fermention medium is according to host's difference and different.Selecting intestinal bacteria for use is the host, is under the situation of expression vector with the pET serial carrier, and fermention medium can be preferably the TB substratum for LB, TB, M9CA etc.Leavening temperature is 30-40 ℃, is preferably 37 ℃; PH6.5-7.5 is preferably pH7.0; Dissolved oxygen DO 〉=30%, inducing the IPTG final concentration of usefulness is 0.3-1.0mM, is preferably 0.5mM; Induction time is 3-5h, is preferably 3.5h.Under above-mentioned suitable condition, can make fermented liquid concentration reach that 30g bacterium weight in wet base/more than the L fermented liquid, the purpose fusion protein expression is more than 25%.
In order to obtain the pure product of rhPTH (1-34) polypeptide, at first be dissolved in the lysate with the fusion rotein of the broken bacterium method of high-pressure homogenization with emiocytosis; Carry out preliminary purification with nickel ion chelating affinity chromatography then, sample behind the preliminary purification is cut with the enteropeptidase enzyme, sample after enzyme is cut carries out chromatography with anion-exchange column, collection penetrates protein solution, to penetrate protein solution and cross the reversed phase chromatography post, and at last sample be crossed cationic exchange coloum and removed organic solvent and obtain rhPTH (1-34) albumen stoste.Utilize this method, 70 liters of fermented liquids can about 2000g weight in wet base thalline, can obtain about 3.5g rhPTH (1-34) albumen stoste by purifying.
Pharmacodynamics test, toxicology test and studies show that before clinical: rhPTH (1-34) subcutaneous injection of the present invention's preparation has the effect of remarkable promotion scleroblast bone forming, and its safe dose is 15 μ g/kg.Therefore, to be used for human body therapy be safely and effectively to the rhPTH (1-34) of the present invention preparation.
In sum, hPTH (1-34) and hydrophilic Trx are merged in the present invention, and this fusion rotein is expressed with soluble form in born of the same parents, has avoided the lower renaturing inclusion bodies step of complex process and yield.Fusion rotein N end contains His-Tag, can pass through Ni
2+Huge legendary turtle and affinity chromatography fast, purifying simply, efficiently, improved the rate of recovery greatly.In the preferred embodiments of the present invention scheme, there is the enteropeptidase cleavage site between Trx and hPTH (1-34), guarantee that the fusion rotein of purifying can discharge complete hPTH (1-34) through the enteropeptidase cutting.Adopt enteropeptidase with the fusion rotein enzymolysis that gives expression to, and utilize a series of column chromatography that target protein hPTH (1-34) purifying is come out, purity can reach more than 99%, even reaches 100%.
Below will be with the example of intestinal bacteria as the host, the mode by specific embodiment is illustrated the present invention, but is to be understood that these embodiment do not limit this in any form
Invention scope.
According to hPTH (1-34) aminoacid sequence (seeing Table 1), according to the e. coli codon preferences, the dna sequence dna of the suitable escherichia coli expression that synthetic is optimized.When synthesizing hPTH (1-34) gene, introduce KpnI restriction enzyme site GGTACC at 5 of this gene ' end, introduce termination codon TAA and SalI restriction enzyme site GTCGAC at 3 ' end, and 5 ' KpnI restriction enzyme site back that end is introduced adds that the enteropeptidase enzyme cuts the encoding sequence GACGACGACGACAAG of recognition site, obtains sequence 1 (see figure 10).For ease of later subclone, synthetic gene is cloned on the pUC18, be used to preserve this synthetic dna sequence dna.Plasmid pUC18 contains KpnI identical with plasmid pET32a (+) and SalI restriction enzyme site.
Table 1, hPTH (1-34) codon use table
| Sequence number | Amino acid | Selected codon | Optional codon | Not |
| 1 | Ser | TCC | TCT，TCA，TCG，AGT，AGC | |
| 2 | Val | GTT | GTC，GTA，GTG | |
| 3 | Ser | TCC | TCT，TCA，TCG，AGT，AGC | |
| 4 | Glu | GAA | GAG | |
| 5 | Ile | ATC | ATT | ATA |
| 6 | Gln | CAG | CAA | |
| 7 | Leu | CTG | TTA，TTG，CTT，CTC | CTA |
| 8 | MET | ATG | ||
| 9 | His | CAC | CAT | |
| 10 | Asn | AAC | AAT | |
| 11 | Leu | CTG | TTA，TTG，CTT，CTC | CTA |
| 12 | Gly | GGT | GGC，GGG | GGA |
| 13 | Lys | AAA | AAG | |
| 14 | His | CAC | CAT | |
| 15 | Leu | CTG | TTA，TTG，CTT，CTC | CTA |
| 16 | Asn | AAC | AAT | |
| 17 | Ser | TCC | TCT，TCA，TCG，AGT，AGC | |
| 18 | Met | ATG | ||
| 19 | Glu | GAA | GAG | |
| 20 | Arg | CGT | CGC | CGA， CGG， AGA， AGG |
| 21 | Val | GTT | GTC，GTA，GTG |
| 22 | Glu | GAA | GAG | |
| 23 | Trp | TGG | ||
| 24 | Leu | CTG | TTA，TTG，CTT，CTC | CTA |
| 25 | Arg | CGT | CGC | CGA， CGG， AGA， AGG |
| 26 | Lys | AAA | AAG | |
| 27 | Lys | AAA | AAG | |
| 28 | Leu | CTG | TTA，TTG，CTT，CTC | CTA |
| 29 | Gln | CAG | CAA | |
| 30 | Asp | GAC | GAT | |
| 31 | Val | GTT | GTC，GTA，GTG | |
| 32 | His | CAC | CAT | |
| 33 | Asn | AAC | AAT | |
| 34 | Phe | TTC | TTT |
Annotate: aminoacid sequence is from the N end beginning label of hPTH polypeptide.
Following molecule clone technology working method, if no special instructions, equal reference literature: molecular cloning experiment guide (Huang Peitang etc. translate, work such as [U.S.] Sa nurse Brooker, Science Press, 2002).Used DNA extraction test kit (UNIQ-10), DNA glue reclaims test kit (UNIQ-10) and connection test kit etc. available from Shanghai Sangon Biological Engineering Technology And Service Co., Ltd in the DNA operation.Cloning vector pUC18, restriction enzyme are available from Fermentas LifeScience company.Expression vector pET32a (+), intestinal bacteria TOP10 and BL21 (DE3) are all available from Novagen company.The clone is TOP10 with escherichia coli host, and expressing with escherichia coli host is BL21 (DE3).BL21 (DE3) genotype is: hsdS gal (λ cIts857ind1 Sam7 nin5 lacUV5-T7 geneI).BL21 (DE3) has the T7RNA pol gene, and the T7RNA polymerase produces in a large number under the inducing of IPTG, thereby has opened expression of exogenous gene, can make exogenous gene high-efficient expressed.
1. preparation target gene fragment
Extract the pUC18 plasmid DNA that contains hPTH (1-34) encoding sequence with DNA extraction agent box, use the KpnI/SalI double digestion, agarose gel electrophoresis 1% separates small segment, cutting-out contains the segmental gel in the 130bp left and right sides, reclaim test kit with gel DNA and reclaim 130bp left and right sides fragment, electrophoresis checking back is standby.
2. prepare the expression vector fragment
Extract pET32a (+) plasmid DNA with DNA extraction agent box, use the KpnI/SalI double digestion, 1% agarose gel electrophoresis separates big fragment, downcuts to contain big segmental gel, reclaims test kit with gel DNA and reclaims big fragment, and electrophoresis checking back is standby.
3. construction recombination plasmid pET-PTH (1-34)
1,2 ready dna fragmentations are mixed by different volume ratio (2/8,3/7,4/6,5/5), connect 30min with the T4DNA ligase enzyme at 16 ℃, connect product transformed into escherichia coli TOP10 competent cell, coat LB agarose plate (1% peptone that contains 100 μ g/ml Amp, 0.5% yeast extract paste, 1%NaCl, 2% agar)), 37 ℃ of overnight incubation.
4. recombinant screen
10 bacterium colonies of picking contain 37 ℃ of overnight incubation in the LB substratum of 100 μ g/ml Amp at 5ml, extract plasmid DNA with DNA extraction agent box.With EcoR, PstI the DNA enzyme that is extracted is cut respectively, carried out 1% agarose gel electrophoresis evaluation recon then.Because EcoRI is single restriction enzyme site in pET32a (+), removed by the KpnI/SalI double digestion when making up recon, so recon can not be cut by EcoRI; And the single site of the PstI among the pET32a (+) is not or not the polyclone district, and contain a PstI site in rhPTH (1-34) gene, so when cutting pET32a (+) vector plasmid with the PstI enzyme, obtaining molecular weight is the unique DNA fragment of 5.9kb, and recombinant plasmid is cut two dna fragmentations (seeing also Fig. 1) that occur about 1.2kb and 4.7kb with the PstI enzyme.Restriction analysis is the result show, 10 bacterium colonies are correct recon, correct recombinant plasmid called after pET-PTH (1-34).
5. the sequencing of plasmid pET-PTH (1-34):
Recombinant plasmid pET-PTH (1-34) is carried out sequence verification, and the forward sequencing result is seen Fig. 2, and backward sequencing the results are shown in Figure 3.Wherein encoding fusion protein Trx-contains (His)
6As follows with the nucleotide sequence of the connection peptides-Rat parathyroid hormone 1-34 1-34 peptide of enteropeptidase recognition site:
ATGAGCGATAAAATTATTCACCTGACTGACGACAGTTTTGACACG
GATGTACTCAAAGCGGACGGGGCGATCCTCGTCGATTTCTGGGC
AGAGTGGTGCGGTCCGTGCAAAATGATCGCCCCGATTCTGGATG
AAATCGCTGACGAATATCAGGGCAAACTGACCGTTGCAAAACTG
AACATCGATCAAAACCCTGGCACTGCGCCGAAATATGGCATCCG
TGGTATCCCGACTCTGCTGCTGTTCAAAAACGGTGAAGTGGCGGC
AACCAAAGTGGGTGCACTGTCTAAAGGTCAGTTGAAAGAGTTCC
TCGACGCTAACCTGGCCggttctggttctggccatat
gcaccatcatcatcatcattcttctg
gtctggtgccacgcggttctggtatgaaagaaaccgctgctgctaaattcgaacgccagcacatggacag
cccagatctgggtacc
gacgacgacaagTCCGTTTCCGAAATCCAGCTGAT
GCACAACCTGGGTAAACACCTGAACTCCATGGAACGTGTTGA
ATGGCTGCGTAAAAAACTGCAGGACGTTCACAACTTCTAA。Wherein, the sequence that the non-black-body capitalization is formed is the Trx encoding sequence, and the sequence that lowercase is formed is to contain Trx-to contain (His)
6With the connection peptides encoding sequence of proteolytic enzyme recognition site coding region, the italics that has underscore partly is (His)
6Coding region, two line partly are enteropeptidase recognition site coding regions, and the sequence that bold race capital is formed is hPTH (1-34) dna sequence dna, and the TAA of italic is a terminator codon.HPTH (1-34) dna sequence dna and Design Theory in the engineering bacteria that the order-checking proof makes up are in full accord.In addition, need to prove, in the encoding sequence of above-mentioned fusion rotein, in the connection peptides encoding sequence that lowercase is formed (His)
6-Tag and enteropeptidase coding region are essential sequences for obtaining pure hPTH (1-34), so other sequence in the lowercase is dispensable, and also replaceable have the sequence of function for other.
The abduction delivering of embodiment 3 engineering bacterias
With recombinant plasmid pET-PTH (1-34) DNA transformed into escherichia coli BL21 (DE3), the resulting genetic engineering bacterium that is used to express rhPTH (1-34) fusion rotein that is.8 single bacterium colonies of picking, 5ml contain 100 μ g/ml Amp the LB substratum (1% peptone, 0.5% yeast extract paste, 1%NaCl) in 37 ℃ of overnight incubation, transferring with 1/100 volume contains 37 ℃ of cultivations in the LB substratum of 100 μ g/ml Amp in 50ml, and residue bacterium liquid is frozen with 15% glycerine packing.OD
600Reach at 0.5 o'clock, add IPTG and carry out abduction delivering to final concentration 0.5mM, the SDS-PAGE electrophoresis is carried out in sampling after 4 hours.Compare with the contrast of inductive not, the recon after inducing all has the expression band about expection molecular weight 20kDa, and expression amount is more than 25% of whole bacterial protein.Get the highest bacterium of output No. 6 as engineering bacteria, called after BL21 (DE3)-PTH (1-34) puts in the glycerine and preserves.Protein expression screening electrophorogram is seen accompanying drawing 4.
The fermentation of embodiment 4 engineering bacteria BL21 (DE3)-PTH (1-34)
Get 1 of the glycerine bacterial classification (1mL) of engineering bacteria BL21 (the DE3)-PTH (1-34) that expresses Trx-hPTH, be inoculated into 400mL LB substratum (1% peptone, 0.5% yeast extract paste, 1%NaCl) in, 37 ℃, 200rpm shake-flask culture 14-16h, activated seed.Get activated seed and be connected to (1.2% peptone, 2.4% yeast extract paste, 0.4% glycerine, 17mM KH in the 3.5L TB substratum by 10% inoculum size
2PO
4, 72mM K
2HPO
4) (5L B.Braun fermentor tank), cultivate 3-4h for 37 ℃.Then this nutrient solution is connected to by 5% inoculum size that (100L B.Braun fermentor tank) ferments in the 70L TB substratum, temperature is 37 ℃, pH7.0, DO 〉=30%, is cultured to OD
600=4.0 o'clock begin abduction delivering, and the IPTG final concentration of inducing usefulness is 0.5mM, and induction time is 3-4h.With this understanding, can make fermented liquid concentration reach that 30g bacterium weight in wet base/more than the L fermented liquid, the purpose fusion protein expression is more than 25%.The result sees also Fig. 5.
The purifying of embodiment 5 rhPTH (1-34)
Adopt to connect speed scheming (the CEPA Z41 that wanders about as a refugee, B.Braun company, Germany) the fermentation thalline among the collection embodiment 4, with buffer A (10mM PBS (phosphate buffered saline buffer), 500mM NaCl, 30mM imidazoles, pH8.0) suspend, use APV-1000 high pressure homogenizer (APV Co. Denmark) to break bacterium then, the fusion rotein of emiocytosis is dissolved in the buffer A the centrifugal 30min of 9000rpm.Getting supernatant liquor adopts following method that rhPTH (1-34) is carried out purifying successively:
1. nickel ion chelating affinity chromatography
High-pressure homogenization is broken on the bacterium supernatant liquor in using buffer A equilibrated nickel ion chelating affinity chromatography (Chelating Sepharose Fast Flow, GE Healthcare) post, behind the buffer A thorough washing, with buffer B (10mM PB, 500mM NaCl, 200mM imidazoles, pH8.0) wash-out, collect elution peak, obtain fusion protein sample.
2. the enzyme of fusion rotein is cut
Preparation endonuclease reaction liquid, it is composed as follows: 1mg/mL fusion rotein, 50mMTris-HCl (pH8.0), 1mM CaCl
2, enteropeptidase (ratio in 1mg enteropeptidase cutting 5mg fusion rotein adds enteropeptidase).25 ℃ of enzymes were cut 20 hours.
3. anion exchange chromatography
Enzyme is cut the back protein solution be splined on (50mM Tris-HCl, pH8.0) equilibrated Q Sepharose High Performance (GE Healthcare) chromatography column with damping fluid C.The theoretical iso-electric point of rhPTH (1-34) is 8.29, and is positively charged when pH8.0, do not combine with anion-exchange column, and foreign protein then combines with anion-exchange column because of electronegative.Collection penetrates liquid, can obtain purity and be rhPTH (1-34) protein sample more than 95%.
4. reversed phase column chromatography
Select for use reversed-phase column Source 15RPC (GE Healthcare) to carrying out polishing purification by the rhPTH that obtains through the ion-exchange chromatography purifying mentioned above (1-34) protein sample, make gradient elution with 24-64% ethanol, occur rhPTH (1-34) albumen elution peak when 40-60% ethanol, purity reaches more than 98%.
5. cation exchange column chromatography
With the sample of reversed-phase column wash-out damping fluid D (10mM PB, pH7.0) after the dilution, go up in through damping fluid D equilibrated SP Sepharose Fast Flow (GE Healthcare) chromatography column, behind the damping fluid D thorough washing, with the damping fluid D wash-out that contains 400mM NaCl, obtain purity greater than 99% rhPTH (1-34) albumen.
Respectively go on foot the purification effect (see figure 6) with the SDS-PAGE electrophoretic analysis.
The calibrating of embodiment 6 rhPTH (1-34)
1, SDS-PAGE purity check
Adopt the Tris-Tricine SDS-PAGE (Guo Yaojun of system, protein electrophorese experimental technique, Science Press, 1999) carry out non-reduced type electrophoresis, with Bio-Rad Gel Doc 2000 gel imaging system sweep measurings, rhPTH (1-34) purity is 100% (seeing the 7th road among Fig. 6).
2, RP-HPLC purity check
With the purity of HPLC method mensuration protein and peptide class, accuracy height and its retention time also can be used as index qualitatively.Chromatography column is Delta-Pak C18 5 μ m 3.9 * 150 (Waters Co.), and (0.1% trifluoroacetic acid (TFA) is at 95%dH for buffer A
2In O and 5% acetonitrile) (0.1%TFA is 95% and 5%dH to buffer B
2Among the O) linear gradient elution 70min, flow velocity 1ml/min, 220nm ultraviolet detection.Analytical results shows that the HPLC collection of illustrative plates of the rhPTH of above-mentioned prepared (1-34) is a simple spike, and purity is 100%.The RP-HPLC analytical results is seen Fig. 7.
3, N, C-terminal amino acid sequence analysis
Employing Edman edman degradation Edman mensuration obtains terminal 15 aminoacid sequences of rhPTH (1-34) N-according to embodiment 5 purifying:
Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu; Adopt terminal 3 aminoacid sequences of carboxypeptidase y method mensuration rhPTH (1-34) C-to be: His-Asn-Phe.N, C-terminal amino acid sequence analysis result and theoretical sequence are identical, illustrate that rhPTH (1-34) primary structure that we prepare is correct.
4, the mass spectroscopy of rhPTH (1-34)
The LCQ-Classic mass spectrograph of employing Finnigan company carries out mass spectroscopy to the rhPTH (1-34) of purifying, and the molecular weight that records rhPTH (1-34) is the 4117.5Da (see figure 9).Consistent with the theoretical value (4118.8Da) of rhPTH (1-34).
5, intracellular toxin and pyrogen test
According to the regulation of " biological products bacterial endotoxin test rules " in " Chinese biological goods rules " (version in 2000), the endotoxin content that detects prepared rhPTH (1-34) sample with limulus reagent test is not higher than 10EU/20 μ g rhPTH (1-34).According to the regulation of " Chinese biological goods rules " (version in 2000) " biological products pyrogen test rules ", it is negative to adopt the rabbit method to measure its pyrogen.
Inoculation UMR-106-01 cell (available from ATCC) in 96 porocyte culture plates, inoculum size is 1～2 * 10
5Individual cell/mL, 100 μ L/ holes, 37 ℃, 5%CO
2Overnight incubation.Wash cell once with serum free medium, add substratum and (contain 20mM Hepes, 0.1% bovine serum albumin, and 0.2mM IBMX (3-isobutyl-1-methylxanthine, Sigma), pH7.4) 180 μ L, add 20 μ L again and be diluted to the hPTH (1-34) and the standard substance (available from WHO biological product standards product laboratories (NIBSC)) thereof of different concns, establish the contrast that contains and do not contain IBMX simultaneously, all do two multiple holes with this substratum, 37 ℃, 5%CO
2Hatch 45min.Remove substratum, every hole adds 200 μ L 0.1N HCl, incubation 30min, and fully lysing cell is got supernatant and is adopted cAMP (low pH) KIT (R﹠amp; D company, Cat No.DE0355) mensuration cAMP value.Data utilize computer software to handle, and press following formula formula calculation result:
The result shows that we rhPTH (1-34) of preparation has identical biological activity with the WHO reference substance, and its specific activity is greater than 1.0 * 10
5U/mg rhPTH (1-34).
Embodiment 8 Pharmacodynamic test of active extract
Use rat ovary and extract (ovanceclomiwd, OVX) method is set up simulation primary osteoporosis model, gives to observe bone amount, bone biomechanical, the relevant blood with bone metabolism of bone norphometry, its result of treatment of urine biochemical indicator comprehensive evaluation after 8 weeks of rhPTH (1-34) treatment.Test-results shows:
1) ovariectomy 12 week the group rats the uterus weight in wet base obviously vacation pluck the ovum group and reduce, bone amount (femur and lumbar spine bmd) and bone biomechanical property (femur three-point bending load, lumbar vertebrae compressive load) all vacation pluck the ovum group and obviously reduce, show that the osteoporosis rat model is set up due to the estrogen deficiency;
2) rhPTH (1-34) has obvious result of treatment to OVX induced osteoporosis rat.RhPTH (1-34) treated for 8 weeks, low dosage (10 μ g/Kg) group promptly shows obvious raising effect to femur, lumbar vertebra amount (dry weight, heavy, the bone density of ash) biomechanical property (femur three-point bending ultimate load, lumbar vertebrae compression ultimate load) and the lumbar vertebra girder area of model osteoporosis rat, and improves with the therapeutic dose increase.
Blood calcium phosphorus has the fluctuation change of increasing and descend when 3) observing rhPTH (1-34) injection 4h in this experiment, and is normal behind the 24h.
Therefore, rhPTH (1-34) has the effect of remarkable promotion scleroblast bone forming, and osteoporosis rat is had obvious result of treatment.
Sequence table
＜110〉Shenzhen City HuaShengYuan Gene Engineering Development Co., Ltd
＜120〉contain fusion rotein and the expression vector thereof of human parathyroid hormone 1-34
<130>FI-060212-59
<160>2
<170>PatentIn version 3.2
<210>1
<211>117
<212>DNA
<213>Artificial
<220>
＜223〉encoding sequence of enteropeptidase recognition site-human parathyroid hormone 1-34 peptide
<400>1
gacgacgacg acaagtccgt ttccgaaatc cagctgatgc acaacctggg taaacacctg 60
aactccatgg aacgtgttga atggctgcgt aaaaaactgc aggacgttca caacttc 117
<210>2
<211>576
<212>DNA
<213>Artificial
<220>
＜223〉coding contains the nucleotide sequence of the fusion rotein of Trx and human parathyroid hormone 1-34
<400>2
atgagcgata aaattattca cctgactgac gacagttttg acacggatgt actcaaagcg 60
gacggggcga tcctcgtcga tttctgggca gagtggtgcg gtccgtgcaa aatgatcgcc 120
ccgattctgg atgaaatcgc tgacgaatat cagggcaaac tgaccgttgc aaaactgaac 180
atcgatcaaa accctggcac tgcgccgaaa tatggcatcc gtggtatccc gactctgctg 240
ctgttcaaaa acggtgaagt ggcggcaacc aaagtgggtg cactgtctaa aggtcagttg 300
aaagagttcc tcgacgctaa cctggccggt tctggttctg gccatatgca ccatcatcat 360
catcattctt ctggtctggt gccacgcggt tctggtatga aagaaaccgc tgctgctaaa 420
ttcgaacgcc agcacatgga cagcccagat ctgggtaccg acgacgacga caagtccgtt 480
tccgaaatcc agctgatgca caacctgggt aaacacctga actccatgga acgtgttgaa 540
tggctgcgta aaaaactgca ggacgttcac aacttc 576
Claims (10)
1. fusion rotein is characterized in that having:
(1) sequence of Trx; With
(2) be positioned at the Rat parathyroid hormone 1-34 1-34 peptide in described Trx downstream.
2. the described fusion rotein of claim 1, wherein this fusion rotein also has:
(3) connection peptides that contains the proteolysis enzyme recognition site between described Trx and described Rat parathyroid hormone 1-34 1-34 peptide.
3. the described fusion rotein of claim 2, wherein said proteolysis enzyme recognition site is the enteropeptidase recognition site.
4. the described fusion rotein of claim 3, the N that the C end of wherein said enteropeptidase recognition site directly connects described Rat parathyroid hormone 1-34 1-34 peptide holds.
5. the described fusion rotein of claim 4, wherein this fusion rotein also has:
(4) the C end of choosing wantonly that is arranged in described connection peptides or described Trx or (His) of N end
6-Tag.
6. the described fusion rotein of claim 5, wherein the sequence of this fusion rotein holds the C end to be from N: Trx-(His)
6-enteropeptidase recognition site-Rat parathyroid hormone 1-34 1-34 peptide.
7. the recombinant DNA sequence of each described fusion rotein among the claim 1-6 that encodes.
8. the described recombinant DNA sequence of claim 7 wherein comprises the following nucleotide sequences of the enteropeptidase recognition site-Rat parathyroid hormone 1-34 1-34 peptide in the encoding said fusion protein:
GACGACGACGACAAGTCCGTTTCCGAAATCCAGCTGATGCACAA
CCTGGGTAAACACCTGAACTCCATGGAACGTGTTGAATGGCTGC
GTAAAAAACTGCAGGACGTTCACAACTTC。
9. expression vector, it contains claim 7 or 8 described recombinant DNA sequences under promotor control.
10. the described expression vector of claim 9, wherein the nucleotide sequence of encoding said fusion protein is as follows:
ATGAGCGATAAAATTATTCACCTGACTGACGACAGTTTTGACACG
GATGTACTCAAAGCGGACGGGGCGATCCTCGTCGATTTCTGGGC
AGAGTGGTGCGGTCCGTGCAAAATGATCGCCCCGATTCTGGATG
AAATCGCTGACGAATATCAGGGCAAACTGACCGTTGCAAAACTG
AACATCGATCAAAACCCTGGCACTGCGCCGAAATATGGCATCCG
TGGTATCCCGACTCTGCTGCTGTTCAAAAACGGTGAAGTGGCGGC
AACCAAAGTGGGTGCACTGTCTAAAGGTCAGTTGAAAGAGTTCC
TCGACGCTAACCTGGCCGGTTCTGGTTCTGGCCATATGCACCATC
ATCATCATCATTCTTCTGGTCTGGTGCCACGCGGTTCTGGTATGA
AAGAAACCGCTGCTGCTAAATTCGAACGCCAGCACATGGACAGC
CCAGATCTGGGTACCGACGACGACGACAAGTCCGTTTCCGAAAT
CCAGCTGATGCACAACCTGGGTAAACACCTGAACTCCATGGAAC
GTGTTGAATGGCTGCGTAAAAAACTGCAGGACGTTCACAACTTC。
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100709954A CN100484958C (en) | 2006-03-31 | 2006-03-31 | Fusion protein containing haman parathyroxin 1-34 and its expression vector |
| PCT/CN2007/001024 WO2007112676A1 (en) | 2006-03-31 | 2007-03-29 | A human parathyroid hormone 1-34 fusion protein and expression vectors thereof |
| HK07105962.6A HK1098489A1 (en) | 2006-03-31 | 2007-06-06 | A fusion protein comprising human parathyroid hormone 1-34 and expression vector thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100709954A CN100484958C (en) | 2006-03-31 | 2006-03-31 | Fusion protein containing haman parathyroxin 1-34 and its expression vector |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1900120A true CN1900120A (en) | 2007-01-24 |
| CN100484958C CN100484958C (en) | 2009-05-06 |
Family
ID=37656127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100709954A Active CN100484958C (en) | 2006-03-31 | 2006-03-31 | Fusion protein containing haman parathyroxin 1-34 and its expression vector |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN100484958C (en) |
| HK (1) | HK1098489A1 (en) |
| WO (1) | WO2007112676A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102191303A (en) * | 2010-11-26 | 2011-09-21 | 扬子江药业集团北京海燕药业有限公司 | Method for expressing and preparing gene recombinant Talpha1 |
| CN107941983A (en) * | 2018-01-05 | 2018-04-20 | 北京博康健基因科技有限公司 | A kind of rhPTH albumen or the detection method of rhPTH protein formulations and the analysis method of purity |
| CN110938151A (en) * | 2019-12-30 | 2020-03-31 | 重庆艾力彼生物科技有限公司 | Fusion protein for expressing parathyroid hormone PTH, recombinant plasmid and recombinant engineering bacteria |
| CN112646826A (en) * | 2020-12-23 | 2021-04-13 | 无锡和邦生物科技有限公司 | Gene sequence for coding Trx-hPTH (1-34) fusion protein, recombinant expression plasmid, engineering bacterium and application |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011151721A1 (en) | 2010-06-04 | 2011-12-08 | Lupin Limited | Process for production of fusion proteins using truncated e. coli thioredoxin |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1189565C (en) * | 2000-09-18 | 2005-02-16 | 中山大学 | Efficient prokaryotic expression carrier |
| CN1424325A (en) * | 2001-12-12 | 2003-06-18 | 中国科学院上海生物工程研究中心 | Production of reorganized human parathyroid hormone 1-34 peptide |
| CN1212336C (en) * | 2002-11-29 | 2005-07-27 | 西南生物工程产业化中试基地有限公司 | Prepn of recombinant human parathyroid hormone PTH (1-34) |
| CN1706947A (en) * | 2004-06-04 | 2005-12-14 | 南京大学生物制药工程研究中心 | Construction, expression and purification method of recombinant human parathyroid hormone in colibacillus |
| CN1807456B (en) * | 2005-01-19 | 2012-09-05 | 丁邦 | Recombinant human parathormone PTH1-34 preparation method |
-
2006
- 2006-03-31 CN CNB2006100709954A patent/CN100484958C/en active Active
-
2007
- 2007-03-29 WO PCT/CN2007/001024 patent/WO2007112676A1/en active Application Filing
- 2007-06-06 HK HK07105962.6A patent/HK1098489A1/en unknown
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102191303A (en) * | 2010-11-26 | 2011-09-21 | 扬子江药业集团北京海燕药业有限公司 | Method for expressing and preparing gene recombinant Talpha1 |
| CN107941983A (en) * | 2018-01-05 | 2018-04-20 | 北京博康健基因科技有限公司 | A kind of rhPTH albumen or the detection method of rhPTH protein formulations and the analysis method of purity |
| CN110938151A (en) * | 2019-12-30 | 2020-03-31 | 重庆艾力彼生物科技有限公司 | Fusion protein for expressing parathyroid hormone PTH, recombinant plasmid and recombinant engineering bacteria |
| CN110938151B (en) * | 2019-12-30 | 2023-03-17 | 重庆艾力彼生物科技有限公司 | Fusion protein for expressing parathyroid hormone PTH, recombinant plasmid and recombinant engineering bacteria |
| CN112646826A (en) * | 2020-12-23 | 2021-04-13 | 无锡和邦生物科技有限公司 | Gene sequence for coding Trx-hPTH (1-34) fusion protein, recombinant expression plasmid, engineering bacterium and application |
Also Published As
| Publication number | Publication date |
|---|---|
| HK1098489A1 (en) | 2007-07-20 |
| CN100484958C (en) | 2009-05-06 |
| WO2007112676A1 (en) | 2007-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1916172A (en) | Method for preparing parathormone 1-34 | |
| JPH04505259A (en) | Recombinant DNA method for the production of parathyroid hormone | |
| CN1900120A (en) | Fusion protein containing haman parathyroxin 1-34 and its expression vector | |
| CN1807456A (en) | Recombinant human parathormone PTH1-34 preparation method | |
| CN1974601A (en) | New-type Fc fusion protein and its production process | |
| CN101402688B (en) | Fusion protein, encoding gene and uses thereof | |
| CN1873006A (en) | Method for producing recombined human proinsulin | |
| CN1861790A (en) | Preparation process of human recombined parathyroid hormone 1 84 | |
| CN1831012A (en) | Immunological adjuvant with immunity vegulating agent for treating and preventing diabetic from insulin-dependent | |
| CN114933658B (en) | Short peptide element and application method thereof | |
| CN102732549B (en) | Preparation method of recombinant insulin-like growth factor-I (IGF-I) | |
| CN1597697A (en) | Human parathyrin 1.34 peptide related peptide-Pro-Pro-[Arg11 hPTH (1.34)-Pro-Pro | |
| CN1274834C (en) | Man's serum albumin with man's parathormone (1-34) fusion protein and its application | |
| WO2007068053A1 (en) | Recombinant protein production | |
| CN1861635A (en) | Human pancreas hyperglycemiacin relative peptide-2 analogue | |
| CN1295332C (en) | Recombination human alkaline fiber forming cell growth factor gene and its nonfusion expression product, production method and application | |
| CN1844390A (en) | Duck B lymphocyte stimulating factor cDNA and its clone method and recombinant use | |
| CN1212336C (en) | Prepn of recombinant human parathyroid hormone PTH (1-34) | |
| CN1566154A (en) | Novel hepatocyte growth factor, preparing process and application thereof | |
| CN102827290A (en) | Fusion protein of human serum albumin and lipolysis structural domain of human growth hormone | |
| CN101736008B (en) | Method for preparing genetic engineering N-acetylated thymosin alpha1 | |
| CN1888066A (en) | Production process of recombinant human horny cell growth factor-2 | |
| CN1869228A (en) | Production method of recombination human interferon gamma | |
| CN107217069B (en) | Prokaryotic expression vector, rbFGF-2 expression method, engineering bacteria and application | |
| CN109988233B (en) | Recombinant human growth hormone and its coding gene, preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1098489 Country of ref document: HK |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20081205 Address after: KBA green science and Technology City, Dongguan Town, Changping City, Guangdong Province, China: 523581 Applicant after: Dongguan Taili Biotech Co., Ltd. Address before: The postcode of No. 7, No. 1, Nanshan District science and technology, Guangdong, Shenzhen Province, China: 518000 Applicant before: Huashengyuan Gene Engineering Development Co., Ltd., Shenzhen City |
|
| ASS | Succession or assignment of patent right |
Owner name: DONGGUAN TAILI BIOLOGY ENGINEERING CO., LTD. Free format text: FORMER OWNER: SHENZHEN CITY HUASHENGYUAN GENE ENGINEERING DEVELOPMENT CO., LTD. Effective date: 20081205 |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1098489 Country of ref document: HK |
|
| ASS | Succession or assignment of patent right |
Owner name: BOKANGJIAN GENE TECH CO., LTD., BEIJING Free format text: FORMER OWNER: DONGGUAN TAILI BIOTECH CO., LTD. Effective date: 20120110 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 523581 DONGGUAN, GUANGDONG PROVINCE TO: 102200 CHANGPING, BEIJING |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20120110 Address after: 102200 Changping District Spark Street, Beijing, No. 7 Patentee after: Bokangjian Gene Tech Co., Ltd., Beijing Address before: 523581 KBA green science and Technology City, Changping Town, Dongguan City, Guangdong Province Patentee before: Dongguan Taili Biotech Co., Ltd. |